<DOC>
	<DOCNO>NCT00043576</DOCNO>
	<brief_summary>The purpose study determine DN-101 plus Taxotere lower PSA level , delay limit disease progression safe minimal side effect .</brief_summary>
	<brief_title>ASCENT : Androgen Independent Prostate Cancer Study Calcitriol Enhancing Taxotere</brief_title>
	<detailed_description>DN-101 investigational drug approve U.S. Food Drug Administration ( FDA ) . It newly formulate pill contains high amount calcitriol , naturally occur hormone biologically active form vitamin D. Administration DN-101 result much high blood level calcitriol body produce dietary vitamin D vitamin D supplement . These high level calcitriol associate anti-cancer effect laboratory model human cancer . Laboratory model also indicate calcitriol synergy many commonly use chemotherapeutic agent use treat cancer . Calcitriol , low dos , currently approve use patient chronic kidney failure . DN-101 specifically design cancer contain 30 time amount calcitriol find calcitriol pill commercially available today . In order take amount calcitriol equivalent 1 DN-101 pill , cancer patient would need swallow 30 pill approve , low dose formulation . DN-101 represent breakthrough use calcitriol clinic , contain high concentration calcitriol make feasible patient stay regimen .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Three rise PSA measurement OR new metastatic lesion Adequate liver kidney function Ongoing hormonal therapy No hospitalization angina , heart attack congestive heart failure within last 12 month No kidney stone last 5 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen Independent Prostate Cancer</keyword>
</DOC>